RWE : adolescent data from EMPOWER/ENABLE

Pooled data from EMPOWER/ENABLE shed light on outcomes in adolescents with Hereditary
Angioedema (HAE). The study reports the effectiveness and safety of TAKHZYRO in preventing
attacks in patients aged 12–18 years with HAE-C1INH.